Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 15/20 | 0.39 |
| ▸ | DRD4 | P21917 | 15/20 | 0.39 |
| ▸ | DRD3 | P35462 | 15/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26941571 | 0.86 | OPRM1 (0.36) | DRD2DRD4DRD3HSD11B1ALDH1A1 | |
| SCHEMBL24394125 | 0.86 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL24398057 | 0.86 | MAPK1 (0.36) | DRD2DRD4DRD3ALDH1A1SMN1; SMN2 | |
| SCHEMBL26941611 | 0.86 | ALDH1A1 (0.37) | DRD2DRD4DRD3ALDH1A1MAPT | |
| SCHEMBL26958140 | 0.84 | MAPT (0.38) | DRD2DRD4DRD3HSD11B1ALDH1A1 | |
| SCHEMBL24397839 | 0.84 | MAPT (0.38) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL24397848 | 0.83 | HSD11B1 (0.38) | DRD2DRD4DRD3HSD11B1ALDH1A1 | |
| SCHEMBL24397821 | 0.83 | SIGMAR1 (0.35) | ALDH1A1LMNAMAPK1 | |
| SCHEMBL24394104 | 0.83 | THRB (0.37) | — | |
| SCHEMBL24397784 | 0.83 | OPRM1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399287-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-12-14 | — | — | US | disclosed |
| US-20230399287-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-12-14 | — | — | US | disclosed |
| WO-2022090724-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399287-A1 | NOVEL COMPOUNDS | CNKSR1, RORC, HLA-DRB1 | DRD2 2698/4885DRD4 3052/4885DRD3 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.